Mid-cap biotech Neurocrine Biosciences (NBIX)
continues to rack up the good news, but the market is still reluctant
to give full value to the shares. Not only will this company have two
presumptive blockbusters-to-be on the market this year, but it will soon
be profitable at the operating income line and it has two more
potential blockbuster indications lined up relatively soon, as well as
longer-dated and more speculative pipeline opportunities. Although the
company continues to take what I see as a conservative approach with its
pipeline, the switchover to positive free cash flow will create
expanded opportunities for capital deployment for management.
Read the full article here:
Neurocrine Biosciences - 2 Blockbusters Approved, And Likely More To Come
No comments:
Post a Comment